RET and medullary thyroid gland carcinoma: Mutually exclusive RAS mutations (HRAS and KRAS) have been reported in approximately 15% of sporadic MTC, RET, and RAS proto-oncogene mutations are detected in approximately 90% of MTCs and are the predominant drivers of these tumors.